GeneDx Holdings Corp.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total revenue $196.2m $179.3m $212.2m $234.7m $202.6m $305.4m $427.5m
Gross profit $82.8m $4.0m ($16.6m) ($26.8m) $90.0m $194.4m $298.2m
Research and development $34.9m $72.7m $105.2m $86.2m $58.3m $45.7m $72.0m
Other operating expenses, net $6.3m $7.2m $3.4m $0
Selling and marketing $39.4m $63.2m $112.7m $134.9m $61.0m $67.4m $88.4m
General and administrative $29.5m $206k $206.0m $203.3m $133.8m $101.1m $150.8m
Impairment loss $0 $0 $210.1m $10.4m $0 $0
Loss from operations ($30.4m) ($206k) ($446.1m) ($667.7m) ($180.6m) ($23.2m) ($13.1m)
Change in fair value of financial liabilities $1.2m ($13.4m) ($1.2m)
Loss before income taxes ($29.7m) ($192k) ($245.4m) ($598.0m) ($176.7m) ($52.6m) ($21.1m)
Income tax benefit $0 $0 $0 $49.1m $926k $343k $116k
Net loss ($29.7m) ($192k) ($245.4m) ($549.0m) ($175.8m) ($52.3m) ($21.0m)
Unrealized gain related to available for sale securities, net $0 $425k $405k $106k
Comprehensive loss ($29.7m) ($241.3m) ($245.4m) ($549.0m) ($175.3m) ($51.9m) ($20.9m)
Basic net loss per share, Class A common stock (in dollars per share) ($264k) ($47k) ($2) ($2) ($7) ($2) ($1)
Diluted net loss per share, Class A common stock (in dollars per share) ($264k) ($47k) ($2) ($2) ($7) ($2) ($1)
Basic weighted average shares outstanding of Class A common stock (in shares) 124 5k 108.1m 337.8m 24.3m 26.9m 28.6m
Diluted weighted average shares outstanding of Class A common stock (in shares) 124 5k 108.1m 337.8m 24.3m 26.9m 28.6m
Cost of services $113.4m $175.3m $228.8m $261.4m $112.6m $111.1m $129.4m
Interest (expense) income, net $1.1m ($3.0m) ($2.5m)
Other (expense) income, net $504k $2.6m $5.1m $57k $1.6m ($13.0m) ($4.3m)
Total non-operating (expense) income, net $709k $654k $200.8m $69.6m $3.9m ($29.4m) ($8.1m)